期刊
ONCOTARGET
卷 8, 期 25, 页码 41154-41165出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.17074
关键词
Alzheimer's disease; amyloid; immunoglobulin; Fab; oligomers
资金
- Plan Estatal de I+D+I
- ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion [PI13/00408, PI13/00135, CP10/00548]
- FEDER Funds
- Fundacio La Marato-TV3 [20140210, 20134030]
- Spanish Ministry of Education
- Universitat Autonoma de Barcelona-Programa Banco de Santander Fellowship
- [SAF2014-52228-R]
- [BIO2014-57518-R]
The amyloid beta-peptide (A beta) plays a leading role in Alzheimer's disease (AD) physiopathology. Even though monomeric forms of A beta are harmless to cells, A beta can aggregate into beta-sheet oligomers and fibrils, which are both neurotoxic. Therefore, one of the main therapeutic approaches to cure or delay AD onset and progression is targeting A beta aggregation. In the present study, we show that a pool of human gamma immunoglobulins (IgG) protected cortical neurons from the challenge with A beta oligomers, as assayed by MTT reduction, caspase-3 activation and cytoskeleton integrity. In addition, we report the inhibitory effect of IgG on A beta aggregation, as shown by Thioflavin T assay, size exclusion chromatography and atomic force microscopy. Similar results were obtained with Palivizumab, a human anti-sincitial virus antibody. In order to dissect the important domains, we cleaved the pool of human IgG with papain to obtain Fab and Fc fragments. Using these cleaved fragments, we functionally identified Fab as the immunoglobulin fragment inhibiting A beta aggregation, a result that was further confirmed by an in silico structural model. Interestingly, bioinformatic tools show a highly conserved structure able to bind amyloid in the Fab region. Overall, our data strongly support the inhibitory effect of human IgG on A beta aggregation and its neuroprotective role.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据